Medios AGMEDOF 88 3-Year RORE % is -8.16 as of Mar. 2026. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $71.50. The stock has 2 warning signs investors should review. Among 110 Medical Distribution companies, Medios AG ranks worse than 71.82% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Medios AG's 3-Year RORE % for the quarter that ended in Mar. 2026 was -8.16%.
The industry rank for Medios AG's 3-Year RORE % or its related term are showing as below:
MEDOF's 3-Year RORE % is ranked worse than 71.82% of 110
companies
in the Medical Distribution industry
Industry Median: 14.465
vs MEDOF: -8.16
Medios AG (OTCPK:MEDOF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Medios AG 3-Year RORE % Related Terms
Medios AG 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Medios AG's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Medios AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG 3-Year RORE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Medios AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Medios AG (MEDOF) has a 3-Year RORE % of -8.16 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medios AG and its competitors. According to the industry distribution chart, Medios AG ranks #79 out of 110 companies in the Medical Distribution industry, placing it in the top 71.8%.
Is Medios AG's 3-Year RORE % too high?
Medios AG's current 3-Year RORE % is -8.16. Based on the distribution chart, Medios AG ranks #79 out of 110 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's 3-Year RORE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medios AG ranks #79 out of 110 companies for 3-Year RORE %. This places Medios AG in the lower half of its industry. The industry median 3-Year RORE % is 14.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Distribution company?
The median 3-Year RORE % among Medical Distribution companies is 14.47, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Medios AG and its competitors. For the Medical Distribution industry, the median 3-Year RORE % is 14.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current 3-Year RORE % is -8.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current 3-Year RORE % of -8.16. The stock's GF Value™ is $71.50, compared to a current price of $50.00 — trading 30.1% below its estimated fair value. The current 3-Year RORE % is -8.16. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Medios AG (MEDOF), the current 3-Year RORE % is -8.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 30.1% below its estimated GF Value™ of $71.50.
Key valuation signals for MEDOF:
3-Year RORE %: -8.16
GF Value™: $71.50 vs. price of $50.00 (30.1% below fair value)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
